KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer.

Xiaofei Zhou, Alice Toms, Dave Morton, Xiaohui Wang, Adekemi Taylor, Arvind Dasari, Neeraj Gupta, Caly Chien

J Clin Pharmacol 65(11) 1411-1419

PMID40485075
PMCIDPMC12555101
DOI10.1002/jcph.70051
发表日期2025-06-09
入排依据:The study is a Phase III randomized trial in oncology with a drug intervention and original results, but it is a cardiac safety analysis focusing on QT prolongation, not a report of a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort focused on efficacy outcomes.
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。
摘要

摘要

Fruquintinib is a highly selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved by the US Food and Drug Administration and the European Commission for the treatment of previously treated metastatic colorectal cancer (mCRC), regardless of biomarker status. This study used concentration QT interval (C-QTc) modeling, utilizing data from the phase 3 FRESCO-2 study (NCT04322539) in which patients with mCRC received fruquintinib 5 mg, once daily, or matching placebo in a 28-day cycle, to evaluate the potential of fruquintinib to delay cardiac repolarization. The primary objectives were to assess the relationship between change from baseline in the QTc and plasma concentrations of fruquintinib and its metabolite M11, and to predict placebo-corrected change from baseline in the corrected QT interval (ΔΔQTc) associated with clinically relevant fruquintinib or M11 concentrations. The C-QTc analysis was conducted using 1456 time-matched concentration-change from baseline in the population-based corrected QT interval (ΔQTcP) pairs from 205 patients (fruquintinib n = 137; placebo n = 68). The final C-QTc model was a linear mixed-effects model with the effect of M11 concentration on ΔQTcP. This model estimated that the upper bounds of the 90% CI of the mean ΔΔQTcP at steady-state geometric mean (GM) M11 Cmax, and twice the GM M11 Cmax were 0.0537 and 4.00 ms, respectively. Additional C-QTc analysis, including only fruquintinib concentrations, showed no relationship between ΔQTcP and fruquintinib concentrations. The analysis indicated that fruquintinib administered at the approved clinical dose is not anticipated to cause clinically meaningful QT prolongation.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Observed and model‐predicted ΔQTcP versus M11 concentration. Note: Circles represent individual observations on cycle 1 day 1 and cycle 1 day 21. The blue line represents the model prediction. The shaded region represents the 90% CI of the model prediction, assuming a nominal time of cycle 1 day 21 predose and a baseline QTcP equal to the mean value in the analysis dataset. ΔQTcP, change from baseline in the population‐based corrected QT interval; CI, confidence interval; M11, major metabolite of fruquintinib; QTcP, population‐based corrected QT interval.
非 KM Figure